CA2478456A1 - Polytherapie - Google Patents

Polytherapie Download PDF

Info

Publication number
CA2478456A1
CA2478456A1 CA002478456A CA2478456A CA2478456A1 CA 2478456 A1 CA2478456 A1 CA 2478456A1 CA 002478456 A CA002478456 A CA 002478456A CA 2478456 A CA2478456 A CA 2478456A CA 2478456 A1 CA2478456 A1 CA 2478456A1
Authority
CA
Canada
Prior art keywords
vla
interferon
binding antibody
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478456A
Other languages
English (en)
Inventor
Alfred Sandrock
Nancy Simonian
Michael Panzara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Ma Inc.
Alfred Sandrock
Nancy Simonian
Michael Panzara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc., Alfred Sandrock, Nancy Simonian, Michael Panzara filed Critical Biogen Idec Ma Inc.
Priority to CA002478456A priority Critical patent/CA2478456A1/fr
Publication of CA2478456A1 publication Critical patent/CA2478456A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002478456A 2004-08-20 2004-08-23 Polytherapie Abandoned CA2478456A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002478456A CA2478456A1 (fr) 2004-08-20 2004-08-23 Polytherapie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/603,468 2004-08-20
CA002478456A CA2478456A1 (fr) 2004-08-20 2004-08-23 Polytherapie

Publications (1)

Publication Number Publication Date
CA2478456A1 true CA2478456A1 (fr) 2006-02-23

Family

ID=35874775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478456A Abandoned CA2478456A1 (fr) 2004-08-20 2004-08-23 Polytherapie

Country Status (1)

Country Link
CA (1) CA2478456A1 (fr)

Similar Documents

Publication Publication Date Title
AU2005277343B2 (en) Extended treatment of multiple sclerosis
AU2005306399B2 (en) Treatment for multiple sclerosis
US9533044B2 (en) Methods of treating inflammatory disorders using high concentration natalizumab compositions
EP3202789B1 (fr) Anticorps anti-vla-4
JP2008520717A5 (fr)
AU2012202575B2 (en) Treatment for Multiple Sclerosis
CA2478456A1 (fr) Polytherapie
AU2011232775B2 (en) Extended Treatment of Multiple Sclerosis
CA2478455A1 (fr) Methodes de traitement de la sclerose en plaques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20160407